Booklets and Brochures

Details of and the links to the Publications provided by the IWMF for WMozzies are given below

IWMF volunteers, volunteers from the IWMF Affiliates, and WM researchers have developed publications including Booklets, Treatment Guides, and Facts Sheets to provide the newly diagnosed and veteran patients, as well as their caregivers, with up-to-date information about Waldenström’s Macroglobulinemia and how to treat it.

The IWMF does not warranty the content of these publications. They are made available to you as information, and we encourage you to discuss what may be appropriate to you with your haematologist.

To download publication please click on the relevant LINK.

Basic Immunology  http://www.iwmf.com/BasicImmunology  

By Guy Sherwood, M.D. (English version updated 2014; other versions updated 2007.)
A comprehensive review of immunology as it relates to WM.

 

Glossary of Medical Terms   http://www.iwmf.com/system/files/WM_Glossary.pdf

Written & compiled by Guy Sherwood, M.D., Bret Blakeslee, Sue Herms, & Peter DeNardis, 2012.
This glossary is designed to help patients with WM learn and understand pertinent medical terms that relate to our disease.

Clinical Practice Guide for the Treatment of WM (Australia)   http://www.iwmf.com/system/files/WM_guidelines_FINAL.%20Australia.pdf

By Dipti Talaulikar, M.D., Constantine Tam, M.D., et al, 2016

This booklet is a consensus established by the Australian Medical Scientific Advisory Group, which consists of a panel of haematologists across Australia, and it is provided by  the IWMF Affiliate (WMozzies) in Australia.

Guide to WM and LPL   http://www.iwmf.com/system/files/WMUK_LPL_WM_Final_V2.pdf

By Shirley D’Sa, M.D., 2014.
This brochure is written by Dr. D’Sa, a hematologist/oncologist at University College Hospital, London, UK,  The drugs mentioned in the brochure are noted by their generic names and by their UK-specific trade names and may/may not be available in UK/US (or elsewhere) unless in the context of a clinical trial.

Medical Tests      http://www.iwmf.com/system/files/MedicalTests.pdf

By Guy Sherwood, M.D., 2007.  Revised by Sue Herms and Linda Nelson, 2016.

A reference booklet of medical terms and tests, this revision places particular emphasis on expanding the explanation of the Complete Blood Count and on Immunoglobulins. Tests for beta-2 microglobulin and light chains have been added, as has genetics testing.


Waldenstrom’s Macroglobulinemia: Questions and Answers   http://www.iwmf.com/system/files/Q%26A2017-English.pdf

Revised 2010/2014 Guy Sherwood and Sue Herms
Revised 2017 Sue Herms and Linda Nelson

Designed to address common questions about Waldenstrom’s macroglobulinemia, this booklet, including a full glossary of terms, is a detailed companion to the IWMF webpage, Frequently Asked Questions (FAQ).

Treatment Options Guides

These Treatment Options Guides review drug therapies and treatment guidelines currently used in the management of Waldenstrom’s macroglobulinemia. They are designed to provide patients with some of the necessary information to allow them to participate with their physicians in determining the best course of treatment for their disease.

 

Alkylating Agents and Nucleoside Analogs     http://www.iwmf.com/system/files/Chemo-AlkylatingAgents%26NucleosideAnalogs-English.pdf

By Suzanne Herms, 2016 

This Guide discusses alkylating agents, such as chlorambucil (Leukeran), cyclophosphamide (Cytoxan), melphalan (Alkeran) and bendamustine (Bendeka, Treanda, Levact), as well as nucleoside analogs, such as fludarabine (Fludara) and cladribine (2CdA or Leustatin).

Corticosteroids and Immunomodulators     http://www.iwmf.com/system/files/Corticosteroids%26Immunomodulators-English.pdf

By Suzanne Herms, 2016

This Guide includes corticosteroids, such as prednisone, prednisolone, and dexamethasone, as well as immunomodulators (IMiDs), such as thalidomide (Thalomid), lenalidomide (Revlimid), and pomalidamide (Actimid or Pomalyst).

Monoclonal Antibodies      http://www.iwmf.com/system/files/MonoclonalAntibodies-English.pdf

By Suzanne Herms, 2016

This Guide discusses monoclonal antibodies, such as rituximab (Rituxan or Mabthera), ofatumumab (Arzerra), and alemtuzumab (Campath).

Proteasome Inhibitors      http://www.iwmf.com/system/files/ProteasomeInhibitors-English.pdf

By Suzanne Herms, 2016

This Guide includes proteasome inhibitors, such as bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro).

Targeted Therapies/Pathway Inhibitors      http://www.iwmf.com/system/files/TargetedTherapies-PathwayInhibitors-English.pdf

By Suzanne Herms, 2016

This Guide discusses targeted therapies/pathway inhibitors to B-cell signaling, such as ibrutinib (Imbruvica) and everolimus (RAD001 or Afinitor).